Fuchs

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Retrieved on: 
Monday, November 13, 2023

CARLSBAD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2023 financial results. A strategic realignment was initiated to prioritize long-term growth, focus capital resources on program spend and implement cost savings. As a result, Design now expects its cash, cash equivalents and marketable securities to fund its planned operating expenses through at least the next five years. Additionally, Design announced plans to provide an update on its corporate strategy and priorities, and outline anticipated milestones across its business and clinical- and research-stage pipeline of novel GeneTAC™ small molecules in early 2024.

Key Points: 
  • A strategic realignment was initiated to prioritize long-term growth, focus capital resources on program spend and implement cost savings.
  • As a result, Design now expects its cash, cash equivalents and marketable securities to fund its planned operating expenses through at least the next five years.
  • Additionally, Design announced plans to provide an update on its corporate strategy and priorities, and outline anticipated milestones across its business and clinical- and research-stage pipeline of novel GeneTAC™ small molecules in early 2024.
  • We look forward to sharing more on our near- and long-term strategic priorities as part of a comprehensive update in early 2024.

Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial

Retrieved on: 
Monday, November 6, 2023

The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.

Key Points: 
  • The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.
  • The case was previously presented as a poster and brief talk at the annual Metastatic Breast Cancer Research Conference in September 2022.
  • Topline results from the ELAINE-1 trial, including this patient, were reported at the European Society for Medical Oncology (ESMO) Congress 2022.
  • 5Jeselsohn R, De Angelis C, Brown M, et al: The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

EQS-News: OHB SE: OHB strengthens capital base to implement corporate strategy, Fuchs family remains long term majority shareholder

Retrieved on: 
Monday, August 7, 2023

OHB SE: OHB strengthens capital base to implement corporate strategy, Fuchs family remains long term majority shareholder

Key Points: 
  • OHB SE: OHB strengthens capital base to implement corporate strategy, Fuchs family remains long term majority shareholder
    The issuer is solely responsible for the content of this announcement.
  • OHB strengthens capital base to implement corporate strategy, Fuchs family remains long term majority shareholder
    KKR plans voluntary public takeover offer for all outstanding shares of OHB at a price of EUR 44.00, the Fuchs family will not sell any shares
    Bremen, 7th August, 2023.
  • To this end, OHB has today signed, amongst others, an investment agreement with KKR and the Fuchs Family Foundation as the majority shareholder of OHB, as well as with investment vehicles controlled by the Fuchs family.
  • Marco Fuchs, CEO of OHB: “Strengthening OHB as an independent, European company and partner for governments and institutions strengthens European security and sovereignty in space.

How the Soviets stole nuclear secrets and targeted Oppenheimer, the 'father of the atomic bomb'

Retrieved on: 
Monday, July 24, 2023

The issues that Nolan depicts are not relics of a distant past.

Key Points: 
  • The issues that Nolan depicts are not relics of a distant past.
  • The new world that Oppenheimer helped to create, and the nuclear nightmare he feared, still exists today.
  • Russian President Vladimir Putin is threatening to use nuclear weapons in his war in Ukraine.
  • Declassified records reveal that Soviet spying on the U.S. atomic bomb effort advanced Moscow’s bomb program, but Oppenheimer was no spy.

Oppenheimer’s perspective

    • Oppenheimer joined the Manhattan Project, a nationwide effort to build an atomic bomb before the Nazis developed one, in 1942.
    • In 1954, at the height of the McCarthy era, Oppenheimer was accused of being a communist and even a Soviet spy.
    • Oppenheimer saw communism as the best defense against the rise of fascism in Europe, which, being of Jewish heritage, was personal for him.

Russian overtures

    • But being targeted and cultivated for recruitment is not the same as being a recruited spy.
    • Oppenheimer rejected the approach, but for reasons that remain unclear, he did not inform authorities for several months.
    • Archives made available after the Soviet Union’s collapse now establish beyond doubt that Oppenheimer was not a Soviet agent.

All the Kremlin’s men

    • “Oppenheimer” focuses on Klaus Fuchs, a brilliant theoretical physicist who fled from Nazi Germany to Britain and became a British naturalized subject.
    • General Leslie Groves, the military commander of the Manhattan Project, later blamed the British for failing to identify Fuchs as a Soviet spy.
    • Other Soviet spies, like the British scientist Alan Nunn May, worked in other parts of the Manhattan Project.
    • These men had multiple motives for betraying U.S. atomic secrets.
    • By the end of World War II, Stalin’s spies had delivered the secrets of the atomic bomb to the Kremlin.

New targets

    • Today, the world stands at the edge of technological revolutions that will transform societies in the 21st century, much as nuclear weapons did in the 20th century: artificial intelligence, quantum computing and biological engineering.
    • Watching “Oppenheimer” makes me wonder whether hostile foreign governments may already have stolen keys to unlocking these new technologies, in the same way the Soviets did with the atom bomb.

One-of-a-kind 911 Classic Club Coupe hits the road for the first time

Retrieved on: 
Tuesday, June 27, 2023

Comedian and collector Jerry Seinfeld personally took possession of the one-off creation based on a 911 Carrera (996 generation) during the annual Porsche Parade being held by the club in Palm Springs, California.

Key Points: 
  • Comedian and collector Jerry Seinfeld personally took possession of the one-off creation based on a 911 Carrera (996 generation) during the annual Porsche Parade being held by the club in Palm Springs, California.
  • The 911 Classic Club Coupe is a one-of-one Sonderwunsch (special wishes) project completed by Porsche Classic in collaboration with the Porsche Club of America (PCA).
  • A ducktail spoiler reminiscent of the 1972 911 Carrera RS 2.7, a double-bubble roof, 18-inch forged aluminum Fuchs wheels and unique paint combine to create a striking resemblance to the Type 997 911 Sport Classic.
  • There, it went through a complete restoration including total disassembly, and strengthening of the body-in-white using both original and newly developed parts.

Porsche 911 Classic Club Coupe Heads to Auction

Retrieved on: 
Friday, June 2, 2023

Atlanta, Georgia, June 02, 2023 (GLOBE NEWSWIRE) -- As one of many very special lots included in the Broad Arrow 75th Anniversary Porsche Auction , the one-off 1999 Porsche 911 Classic Club Coupe will find its owner on June 8, 2023.

Key Points: 
  • Atlanta, Georgia, June 02, 2023 (GLOBE NEWSWIRE) -- As one of many very special lots included in the Broad Arrow 75th Anniversary Porsche Auction , the one-off 1999 Porsche 911 Classic Club Coupe will find its owner on June 8, 2023.
  • The car is a Sonderwunsch Factory One-Off special wishes project completed by Porsche Classic in collaboration with the Porsche Club of America (PCA).
  • A ducktail spoiler reminiscent of the 1973 911 Carrera RS 2.7, a double-bubble roof, 18-inch forged aluminum Fuchs wheels and unique paint combine to create a striking resemblance to the Type 997 911 Sport Classic.
  • Based on a 1998 911 Carrera, the chassis, brakes and engine are taken from the 996.2 911 GT3, the first such model homologated for sale in the U.S.

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023

CARLSBAD, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today provided updates and anticipated upcoming milestones across its clinical and research-stage pipeline of novel GeneTAC™ small molecules and reported first quarter 2023 financial results.

Key Points: 
  • “2023 is poised to be an important year for Design as we work to bring our novel GeneTAC™ small molecules closer to patients suffering from devastating genetic diseases,” said João Siffert, M.D., president and chief executive officer of Design Therapeutics.
  • Design now anticipates presenting initial results from the MAD trial in the third quarter of 2023.
  • R&D Expenses: Research and development (R&D) expenses were $15.7 million for the quarter ended March 31, 2023.
  • Net Loss: Net loss was $19.3 million for the quarter ended March 31, 2023.

Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting

Retrieved on: 
Monday, May 8, 2023

A separate STORM analysis assessed visual morbidity in patients with Fuchs endothelial corneal dystrophy (FECD) prior to surgery using the V-Fuchs Questionnaire (V-FUCHS).

Key Points: 
  • A separate STORM analysis assessed visual morbidity in patients with Fuchs endothelial corneal dystrophy (FECD) prior to surgery using the V-Fuchs Questionnaire (V-FUCHS).
  • The data were presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Diego.
  • The study results showed TTHX1114 improved best-corrected visual acuity (BCVA) and central corneal thickness (CCT) after DSO in the 49 subjects/64 eyes.
  • Faster recovery was associated with smaller descemetorhexis (surgical removal of Descemet membrane), while comorbid diabetes appeared to delay recovery.

New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgery

Retrieved on: 
Monday, April 24, 2023

Across all patients, TTHX1114 produced a dose-dependent response in resolution of corneal edema and improvement of best corrected visual acuity (BCVA) following surgery.

Key Points: 
  • Across all patients, TTHX1114 produced a dose-dependent response in resolution of corneal edema and improvement of best corrected visual acuity (BCVA) following surgery.
  • The proportion of patients with complete resolution of corneal edema in the high-dose groups at 28 days after surgery was similar in patients with DSO vs. those with DSO and cataract surgery (25.9% vs 17.4%).
  • It is exciting to see TTHX1114 perform well in controlling post-surgical edema in at-risk patients undergoing cataract surgery,” said Eveleth.
  • However, visual outcomes for patients undergoing DSO did not appear to be adversely affected by concurrent cataract surgery.

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

Retrieved on: 
Monday, April 24, 2023

CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orleans from April 23-27, 2023.

Key Points: 
  • FECD is characterized by progressive corneal degeneration leading to vision loss and affects millions of people in the U.S.
  • There are no disease-modifying therapies approved for FECD, and advanced cases generally require ocular surgery, including corneal transplant.
  • In preclinical studies, DT-168 reduced foci in patient-derived primary corneal endothelial cells (CECs) to levels seen in cells from healthy individuals with low nanomolar IC50 values.
  • Design remains on-track to submit an Investigational New Drug application for DT-168 for the treatment of FECD in the second half of 2023.